Oasmia Pharmaceutical develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The Company's approved products include Paclical/Apealea, treating cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops a number of candidates to treat cancer comprising leukemia, prostate, lung, breast cancer, and lymphoma. The Company also develops a formulation to treat lymphoma in dogs.
|Employees (est.) (Jul 2019)||55||(-3%)|
|Share Price (Jun 2019)||$4.3||(-8%)|
Market capitalization (5-Jun-2019)
Closing stock price (5-Jun-2019)
Oasmia Pharmaceutical has 580 Twitter Followers. The number of followers has increased 2.1% month over month and increased 3.6% quarter over quarter
When was Oasmia Pharmaceutical founded?
Oasmia Pharmaceutical was founded in 1990.
Who are Oasmia Pharmaceutical key executives?
Oasmia Pharmaceutical's key executives are Sven Rohmann, Anette Sjödin and Nina Heldring.
How many employees does Oasmia Pharmaceutical have?
Oasmia Pharmaceutical has 55 employees.
Who are Oasmia Pharmaceutical competitors?
Competitors of Oasmia Pharmaceutical include Patterson Companies, MolMed and Akrevia Therapeutics.
Where is Oasmia Pharmaceutical headquarters?
Oasmia Pharmaceutical headquarters is located at Vallongatan 1, Uppsala.
Where are Oasmia Pharmaceutical offices?
Oasmia Pharmaceutical has an office in Uppsala.
How many offices does Oasmia Pharmaceutical have?
Oasmia Pharmaceutical has 1 office.
Receive alerts for 300+ data fields across thousands of companies